Sodium‐glucose co‐transporter 2 inhibitors & glucagon‐like peptide‐1 receptor agonists, efficacy & safety in diabetic kidney transplant recipients
Clinical Transplantation · 2023-12 · 37 (12)
DOI: 10.1111/ctr.15144 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, online erschienen am 27.09.2023. Verfasst von Tarek Mahmoud und 8 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Department, Jaber Al Ahmed Armed Forces Hospital, Subhan, Kuwait. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Kidney Transplantation, Symporters. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Introduction
Cardiovascular and renal complications define the outcomes of diabetic kidney transplant recipients (KTRs). The new diabetes medications have changed the management of diabetes. However, transplant physicians are still reluctant to use sodium–glucose cotransporter 2 inhibitors (SGLT2i) and Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) post kidney transplantation due to fear of drug related complications and lack of established guidelines. Patients and methods We collected 1‐year follow‐up data from records of 98 diabetic KTRs on SGLT2I, 41 on GLP‐ 1RA and 70 on standard‐of‐care medicines. Patients were more than 3 months post‐transplant with a minimum estimated glomerular filtration rate (eGFR) of 25 ml/min/1.73 m 2 . Demographic data were similar except for a slightly lower HbA1c in the control group and higher albuminuria in SGLT2i group.
Results
HbA1c dropped significantly by .4% in both SGLT2i and GLP‐1RA compared to .05% in the control group. A significant decrease in BMI by .32 in SGLT2i and .34 in GLP‐1RA was observed compared to an increase by .015 in control group. A tendency for better eGFR in study groups was observed but was non‐significant except for the SGLT2i group with an eGFR above 90 ( p = .0135). The usual dip in eGFR was observed in the SGLT2i group at 1–3 months. Albuminuria was significantly reduced in both study groups. Adverse events were minimal with comparable safety in all groups.
Conclusion
The use of SGLT2i and GLP‐1RA appears to be effective and safe in diabetic KTRs with good outcomes. Randomized control trials are required to confirm these findings and establish guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nephrology Department, Jaber Al Ahmed Armed Forces Hospital, Subhan, Kuwait.
- Nephrology Department, Hamed Al-Essa Organ Transplant Center, Sabah Medical Region, Kuwait City, Kuwait.
- Department of Translational Research, Dasman Diabetes Institute, Dasman, Kuwait.
ORCID-Profile: Tarek Mahmoud, Jude Yagan, Amal Hasan, Osama A Gheith
Zitieren
APA
Mahmoud, T., Yagan, J., Hasan, A., Gheith, O. A., Mostafa, M., Rida, S., El-Serwi, N., Shaker, M., & Khalid, M. (2023). Sodium‐glucose co‐transporter 2 inhibitors & glucagon‐like peptide‐1 receptor agonists, efficacy & safety in diabetic kidney transplant recipients. Clinical Transplantation, 37(12). https://doi.org/10.1111/ctr.15144
Vancouver
Mahmoud T, Yagan J, Hasan A, Gheith OA, Mostafa M, Rida S, et al. Sodium‐glucose co‐transporter 2 inhibitors & glucagon‐like peptide‐1 receptor agonists, efficacy & safety in diabetic kidney transplant recipients. Clinical Transplantation. 2023;37(12). doi:10.1111/ctr.15144
BibTeX
@article{Mahmoud2023,
author = {Mahmoud, Tarek and Yagan, Jude and Hasan, Amal and Gheith, Osama A and Mostafa, Mohamed and Rida, Suzann and El-Serwi, Nabil and Shaker, Mohamad and Khalid, Mahmoud},
title = {Sodium‐glucose co‐transporter 2 inhibitors & glucagon‐like peptide‐1 receptor agonists, efficacy & safety in diabetic kidney transplant recipients},
journal = {Clinical Transplantation},
year = {2023},
volume = {37},
number = {12},
doi = {10.1111/ctr.15144}
}
EUVIMED